Literature DB >> 25704559

Interferons and viruses: an evolutionary arms race of molecular interactions.

Hans-Heinrich Hoffmann1, William M Schneider1, Charles M Rice2.   

Abstract

Over half a century has passed since interferons (IFNs) were discovered and shown to inhibit virus infection in cultured cells. Since then, researchers have steadily brought to light the molecular details of IFN signaling, catalogued their pleiotropic effects on cells, and harnessed their therapeutic potential for a variety of maladies. While advances have been plentiful, several fundamental questions have yet to be answered and much complexity remains to be unraveled. We explore the current knowledge surrounding four main questions: are type I IFN subtypes differentially produced in response to distinct pathogens? How are IFN subtypes distinguished by cells? What are the mechanisms and consequences of viral antagonism? Lastly, how can the IFN response be harnessed to improve vaccine efficacy?
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  innate immunity; interferon subtype; interferons; vaccine adjuvants.; viral antagonism; viruses

Mesh:

Substances:

Year:  2015        PMID: 25704559      PMCID: PMC4384471          DOI: 10.1016/j.it.2015.01.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  190 in total

1.  Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways.

Authors:  Thomas Meyer; Andreas Begitt; Inga Lödige; Marleen van Rossum; Uwe Vinkemeier
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 3.  Innate immune recognition of nucleic acids: beyond toll-like receptors.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

4.  Direct suppression of Stat1 function during adenoviral infection.

Authors:  D C Look; W T Roswit; A G Frick; Y Gris-Alevy; D M Dickhaus; M J Walter; M J Holtzman
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

Review 5.  Dynamic control of type I IFN signalling by an integrated network of negative regulators.

Authors:  Rebecca A Porritt; Paul J Hertzog
Journal:  Trends Immunol       Date:  2015-02-25       Impact factor: 16.687

6.  Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes.

Authors:  B J Barnes; P A Moore; P M Pitha
Journal:  J Biol Chem       Date:  2001-04-12       Impact factor: 5.157

7.  Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity.

Authors:  C K Lee; H A Bluyssen; D E Levy
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

8.  Ligand-induced association of the type I interferon receptor components.

Authors:  B Cohen; D Novick; S Barak; M Rubinstein
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

9.  Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates.

Authors:  Delphine Goubau; Martin Schlee; Safia Deddouche; Andrea J Pruijssers; Thomas Zillinger; Marion Goldeck; Christine Schuberth; Annemarthe G Van der Veen; Tsutomu Fujimura; Jan Rehwinkel; Jason A Iskarpatyoti; Winfried Barchet; Janos Ludwig; Terence S Dermody; Gunther Hartmann; Caetano Reis e Sousa
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

10.  Paramyxovirus mRNA editing leads to G deletions as well as insertions.

Authors:  J P Jacques; S Hausmann; D Kolakofsky
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

View more
  171 in total

1.  Reduction of infection by inhibiting mTOR pathway is associated with reversed repression of type I interferon by porcine reproductive and respiratory syndrome virus.

Authors:  Qinfang Liu; Laura C Miller; Frank Blecha; Yongming Sang
Journal:  J Gen Virol       Date:  2017-06-14       Impact factor: 3.891

2.  IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE.

Authors:  Dan Li; Bharati Matta; Su Song; Victoria Nelson; Kirsten Diggins; Kim R Simpfendorfer; Peter K Gregersen; Peter Linsley; Betsy J Barnes
Journal:  JCI Insight       Date:  2020-01-30

Review 3.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

4.  Long Noncoding RNA Signatures Induced by Toll-Like Receptor 7 and Type I Interferon Signaling in Activated Human Plasmacytoid Dendritic Cells.

Authors:  Rochelle C Joslyn; Adriana Forero; Richard Green; Stephen E Parker; Ram Savan
Journal:  J Interferon Cytokine Res       Date:  2018-09       Impact factor: 2.607

5.  A Cytoplasmic RNA Virus Alters the Function of the Cell Splicing Protein SRSF2.

Authors:  Efraín E Rivera-Serrano; Ethan J Fritch; Elizabeth H Scholl; Barbara Sherry
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection.

Authors:  Kapil Saxena; Lukas M Simon; Xi-Lei Zeng; Sarah E Blutt; Sue E Crawford; Narayan P Sastri; Umesh C Karandikar; Nadim J Ajami; Nicholas C Zachos; Olga Kovbasnjuk; Mark Donowitz; Margaret E Conner; Chad A Shaw; Mary K Estes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

7.  Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.

Authors:  Chi-You Chang; Helene Minyi Liu; Ming-Fu Chang; Shin C Chang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

8.  Mint3 potentiates TLR3/4- and RIG-I-induced IFN-β expression and antiviral immune responses.

Authors:  Wanwan Huai; Hui Song; Zhongxia Yu; Wenwen Wang; Lihui Han; Takeharu Sakamoto; Motoharu Seiki; Lining Zhang; Qunye Zhang; Wei Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

9.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

10.  cFLIPL Interrupts IRF3-CBP-DNA Interactions To Inhibit IRF3-Driven Transcription.

Authors:  Lauren T Gates; Joanna L Shisler
Journal:  J Immunol       Date:  2016-06-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.